Navigation Links
CROI -- Day 2: Selected highlights of NIH-supported research
Date:2/28/2011

ndings presented today, the gel was shown to have a strong antiviral effect when used in the rectum. These results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first evidence that tenofovir gel could help reduce the risk of HIV infection from anal sex, even though the vaginal gel formulation may not be optimal for rectal use. Analysis of rectal tissue samples showed that a single dose of oral tenofovir provided no protection against HIV.

Craig Hendrix, M.D., of the Johns Hopkins University School of Medicine in Baltimore, described results from a Phase II international clinical trial known as MTN-001. This is the first study to directly compare vaginal tenofovir gel and oral tenofovirtwo promising approaches for preventing HIV in women. The researchers found that daily use of the vaginal gel for 6 weeks led to a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet; additionally, a daily dose of the tablet for 6 weeks was associated with a 20-times higher active drug concentration in blood. Overall, most U.S. women in the study favored the tablet over the vaginal gel, while African participants favored the gel and tablet equally.

Race Differences and ART

According to results of a retrospective multi-study analysis presented by Heather Ribaudo, Ph.D., of Harvard University's School of Public Health in Boston, being black was associated with a 40 percent higher risk of failing to control HIV levels with an initial antiretroviral therapy regimen than being white. This finding is based on an examination of data on nearly 2,500 men and women who participated in five clinical trials conducted between 1998 and 2005. This difference could not be explained by any other variable examined, including the treatment regimen or self-reported adherence to it; age or sex; baseline CD4+ T cell level or viral load; disease statu
'/>"/>

Contact: Laura Sivitz Leifman
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Brigham and Womens Hospital selected to participate in Medicare imaging demonstration project
2. Paper by Rhode Island Hospital physician selected among best of 2010 by JACR
3. UCLA selected by Homeland Security to help establish guidelines for firefighter health and safety
4. Selected cells from blood or bone marrow may provide a route to healing blood vessels
5. Kennedy Krieger Institutes Dr. Paul Lipkin selected for national health policy fellowship
6. Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine
7. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
8. MetricStream Selected by SunTrust for Enterprise-Wide GRC
9. MBA HealthGroup Selected as Preferred Partner by VITL
10. BMI of Texas Selected to Participate in Lap-Band Total Care™ Out of Towner Network
11. Harmony Information Systems Selected to Present at Exclusive MAVA Capital Connection 2010 Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... The holidays can be anything but joyous for people ... candles and other allergy triggers. "The dust from ... packed away in dank basements or dusty attics is ... Rachna Shah, an affiliate faculty member at Loyola University ... release. Shah, who is also an allergist at ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... , , , NEW YORK, ... is available in its catalogue. , , ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , ... Cancer Therapeutics in Millions of US$. The US market for Non-Small ...
... ... Diego, CA adds General Motors and Qualcomm to the program! , ... Portland, ME (PRWEB) September 8, 2009 -- Image Sensors ... San Diego, CA. The 3rd annual international event will address the latest trends and technologies ...
... , , , Will ... , , NEW YORK, Sept. 8 MARK ... of Lighthouse International, the 104-year-old non-profit leader in vision healthcare, research, ... in healthcare management, will start in his new role on September ...
... , ... head back to school , ... (PRWEB) September 8, 2009 -- As the unemployment rate in Canada holds steady at 8.6%, more ... the recession. , , , ,CDI College, a career college with 13 campus locations across Canada, ...
... The New York Football Giants are asking their fans to ... EAST RUTHERFORD, N.J., Sept. 8 We heard you bleed BLUE! ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20090908/DC71650LOGO ) , , On ... with the American Red Cross to host a blood drive. The ...
... Sept. 8 Give an Hour(TM), a national nonprofit organization providing ... their loved ones, announces results of its August 2009 survey and ... survey in May 2009. , , Give an ... effectiveness and to determine how programs and services can be adapted ...
Cached Medicine News:Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 2Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 3Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 2Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 3Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:New York Giants to Host American Red Cross Blood Drive 2Health News:Give an Hour(TM)'s Volunteer Mental Health Professionals Provide Nearly $1.7 Million in Services to Iraq and Afghanistan Veterans, Families, and Communities 2
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with ... albeit as a later starter. In 2012, the size of ... RMB12 billion, with the proportion worldwide soaring to 16.3%. It ... market will continue its growth rate by around 20% in ... jump to roughly RMB25 billion. An integrated membrane ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
... ALTO, Calif., Oct. 1 Telik, Inc. (Nasdaq: TELK ... a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination ... nonsmall cell lung cancer (NSCLC) in a leading peer reviewed ... Vol. 4, No. 10. Data on this study were ...
... , MOUNTAIN VIEW, Calif., Oct. 1 IRIDEX Corporation ... FlexFiber(TM) a laser fiber probe intended for effective delivery ... procedures. Introduced at the 2009 American Academy of ... , this consumable product represents an increase in IRIDEX, ...
Cached Medicine Technology:Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer 2IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: